Interphase ribosomal RNA cistron silver staining in refractory anaemias with and without excess blasts

N N Mamaev, G N Salogub, I B Nefedova

Abstract

Aim—To evaluate the haemopoietic function of bone marrow blood forming cells in human myelodysplastic syndromes (MDS) by silver staining of nucleolar organiser regions (AgNORs).

Methods—Nucleoli were investigated in bone marrow blast cells and in erythroid, granulocytic, and megakaryocytic cells from 12 haematologically healthy subjects, and from 26 patients with MDS, including 14 with refractory anaemia (RA), nine with RA with excess blasts (RAEB), and three with RAEB in transformation (RAEB-t). The investigation was performed before treatment using a one step silver staining method. In each case 50 to 100 blasts, promyelocytes, myelocytes, immature (pronormoblastic and basophilic normoblastic) and mature (polychromatic normoblastic) erythroid elements, and megakaryocytes were evaluated for the mean numbers of nucleoli and AgNORs per nucleus. Student’s t test was used to compare the patient and control groups. Other statistical analyses were carried out by the computer assisted “HEMA” system.

Results—Compared with controls, the number of AgNORs in blasts, promyelocytes, myelocytes, immature erythroid elements, and megakaryocytes was decreased, whereas in myelocytes and polychromatic normoblasts it was similar. There was also a difference in the AgNOR scores in blood forming cells from patients with RAEB/RAEB-t vs RA.

Conclusions—The loss of AgNOR sites in cellular series in MDS may result from the decrease of their proliferative potential with disease progression, intrinsic defects in maturation, and extensive apoptosis. (J Clin Pathol: Mol Pathol 1997;50:92–95)

Keywords: myelodysplastic syndromes; secondary acute myeloid leukaemia; nucleolar organiser regions; silver staining

Myelodysplastic syndromes (MDS) are idiopathic haematological disorders characterised by refractory cytopenias of one or more bone marrow cell lineages. Refractory anaemia (RA) is the most common haematological finding in MDS therefore its pathogenesis has been studied more extensively than that of granulocytopoiesis, megakaryocytopoiesis, etc. The evaluation of erythropoiesis in MDS by ferrokinetic techniques showed reduction in total erythroblast numbers, erythrocyte production, and lifespan.1,2 Measurements of S-G/M-phase DNA content by flow cytometry demonstrated that in MDS the number of cells in G1/G0 was significantly lower than normal in five of 24 RA patients with a correspondingly higher number of cells in G1/M.3 It is noteworthy that a tendency towards a decreased number of cells in S-G1/M was also found in RA patients with excess blasts (RAEB),4,5 Using a new immunocytochemical and flow cytometry technology Jensen et al have recently observed significant differences in the proliferative potential of erythroid progenitor fractions in RA patients compared with normal controls and its pronounced decrease with disease progression.6 Finally, an increased proliferative capacity of blasts, and granulocytic and erythroid series, together with extensive apoptosis was revealed recently using a Ki-67 antibody labelling technique.7 The AgNOR method is a cheap and readily available applied alternative to the aforementioned techniques for assessing cell proliferation states. Our findings in patients with leukaemia have shown that the number of AgNORs in bone marrow haemopoietic progenitors closely reflects their proliferative potential8,9 the level of differentiation and maturation,10 and the degree of nuclear ploidy.10,11 The aim of this work was to investigate the mean numbers of nucleoli and AgNORs in bone marrow blasts, erythroid, granulocytic, and megakaryocytic elements from haematologically healthy controls and from 26 patients with different stages of MDS (RA vs RAEB/RAEB in transformation (RAEB-t)).

Patients and methods

The investigation was performed on 26 untreated adult patients with MDS, including 14 with RA, and 12 with RAEB and RAEB-t, who were admitted to our institution. MDS cases were diagnosed from typical clinical and haematological signs, and from cytogenetic findings. Twelve haematologically healthy subjects acted as controls.

Bone marrow smears taken by sternum puncture were air dried, fixed in methanol-glacial acetic acid mixture (3:1), and rinsed thoroughly with distilled water. After repeated air drying the preparations were put into 2N formic acid for 10 minutes, rinsed again and impregnated with a mixture of 50% aqueous solution of silver nitrate with gelatin at 68°C for
Interphase ribosomal RNA citron silver staining in refractory anaemias

Table 1  Clinical findings, laboratory tests, and nucleolar silver staining data from patients with different variants of myelodysplastic syndromes (MDS). Values are means (SEM)

<table>
<thead>
<tr>
<th>MDS types</th>
<th>Patients (n)</th>
<th>Mean age (years)</th>
<th>Blasts</th>
<th>Nucleolar silver staining data</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hb</td>
<td>L</td>
</tr>
<tr>
<td>RA</td>
<td>14</td>
<td>62.5 (4.6)</td>
<td>2.6 (0.3)</td>
<td>103 (28)</td>
</tr>
<tr>
<td>RAEB and</td>
<td>RAEB-t</td>
<td>57.8 (3.2)</td>
<td>4.6 (0.8)</td>
<td>80.4 (21)</td>
</tr>
<tr>
<td>RAEB-t</td>
<td>9 + 3</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Hb = haemoglobin; L = leucocytes; Ph = platelets; pb = peripheral blood; bm = bone marrow; Bl = blasts; Pr = promyelocytes; Mc = megakaryocytes; Er-I = pronormoblasts and basophilic normoblasts; Er-II = polychromatic normoblasts; Mg = megakaryocytes; RA = refractory anaemia; RAEB = refractory anaemia with excess blasts; RAEB-t = refractory anaemia with excess blasts in transformation.

Results
Clinical findings and the results of nucleolus silver staining of bone marrow cells from controls and from MDS patients are presented in table 1 and figure 1.

REFRACTORY ANAEMIA
In controls and patients with RA the fewest numbers of nucleoli were found in blasts and immature erythroid elements. Numbers were intermediate in promyelocytes, myelocytes, and polychromatic normoblasts, and much greater in megakaryocytes. Compared with controls, the mean numbers of nucleoli in blasts and Er-II tended to increase (the difference between indices was insignificant). In Er-I and megakaryocytes the mean numbers of nucleoli in blasts were significantly decreased (p < 0.005 and p < 0.001, respectively).

In controls and patients with RA the maximum numbers of AgNORs per nucleus were found in megakaryocytes, followed by immature erythroid elements (Er-I). The counts were intermediate in blasts, promyelocytes, and Er-II elements, and lowest in myelocytes. Despite the high proliferative state of basic blood forming elements in patients with RA the expected elevation of ribosomal citron staining activity was not detected. The numbers of nucleoli in blasts correlated with those of promyelocytes (r = 0.68, p < 0.002), immature erythroid elements (r = 0.6, p < 0.009) and megakaryocytes (r = 0.64, p < 0.02). The numbers of nucleoli in promyelocytes correlated with those of Er-I (r = 0.61, p < 0.008), in myelocytes the numbers of nucleoli correlated closely with that of Er-I (r = 0.69, p = 0.001) and Er-II (r = 0.58, p < 0.015).

The AgNOR score of promyelocytes correlated closely with that of blasts (r = 0.7, p < 0.015), Er-I (r = 0.86, p < 0.0001), myelocytes (r = 0.71, p < 0.0001), and with the content of bone marrow myelocytes (r = 0.5, p < 0.038) and platelets (r = 0.5, p < 0.038). In addition, the percentage of bone marrow promyelocytes showed significant correlation with the number of bone marrow myelocytes (r = 0.76, p < 0.001) and white cell count (r = 0.8, p < 0.0001). The numbers of AgNORs in erythroid elements correlated closely with the numbers of these cells in bone marrow (r = 0.61, p < 0.01). In megakaryocytes the numbers of nucleoli closely correlated with the level of haemoglobin (r = 0.72, p < 0.0003); the numbers of AgNORs depended on the indices of polychromatic normoblasts (r = 0.83, p < 0.00001) as well as on the peripheral blood content of plasma cells (r = 1.0, p < 0.00001) and erythrocytes (r = 0.67, p < 0.002). No correlation between AgNORs in blasts and myelocytes was observed.

REFRACTORY ANAEMIAS WITH EXCESS BLASTS
Compared with controls, the patients with RAEB and RAEB-t had a decrease in numbers of nucleoli, not only in immature erythroid elements and megakaryocytes but also in promyelocytes and myelocytes. In addition, the mean numbers of nucleoli were similar in blasts, Er-I, and controls.

Compared with nucleoli counts, the changes of AgNORs in blood forming elements from patients with RAEB and RAEB-t were striking. The mean numbers of AgNORs were noticeably decreased in blasts (p < 0.001), promyelocytes (p < 0.05), Er-I (p < 0.001), Er-II (p < 0.002), and megakaryocytes (p < 0.001). The difference between AgNOR counts in blasts, promyelocytes, myelocytes, and polychromatic normoblasts from patients with RAEB and RAEB-t, and those with RA was also significant (p < 0.01 to p < 0.0001). It is also noteworthy that some lower AgNOR counts in the group were detected in patients with RAEB-t whose percentages of blasts in bone marrow and peripheral blood were the highest but haemoglobin concentration and platelet counts were very low. Additional analysis showed that the AgNOR counts in blasts from patients with RAEB was inversely proportional to those of polychromatic normoblasts (r = -0.81, p < 0.0004).
and myelocytes ($r = -0.55$, $p < 0.05$) which seemed to result from the direct inhibitory effect of blasts on RAEB haematopoiesis at the level of maturing erythroid and granulocyte elements. In contrast, the percentage of bone marrow blasts and the mean numbers of nucleoli in blasts were correlated closely with the content of immature erythroid elements in bone marrow ($r = 0.82$, $p < 0.0002$) and their AgNOR nucleoli counts ($r = 0.78$, $p < 0.0006$). Moreover, a highly significant correlation was also found between the numbers of erythrocytes and the numbers of nucleoli in maturing erythroid elements ($r = 0.78$, $p < 0.0006$).

**Discussion**

This study evaluated haematopoiesis in different stages of MDS by enumerating the interphase ribosomal RNA cistron silver staining. Compared with controls, patients with a stable clinical course (RA and RAS) had a tendency to lower AgNOR scores. In addition, a significant loss of AgNORs was found in erythroid elements, promyelocytes, megakaryocytes, and blasts of patients with RAEB and RAEB-t.

Since the numbers of AgNORs in haematopoietic cells reflect their proliferative potential, the level of differentiation, and the degree of nuclear ploidy, the decrease of AgNORs in MDS patients might be attributed to some changes in these cellular parameters. Indeed, the degree of nuclear ploidy in MDS megakaryocytes is known to be much lower than that in controls. Therefore, low AgNOR counts in RA and RAEB non-proliferating megakaryocytes may be explained by hypoploidy of their nuclei. Indeed, it was mentioned earlier that proliferative activity of erythroid elements from patients with MDS was higher than that of controls only in the stable stages of disease, essentially decreasing with progression of MDS from RA to RAEB-t. Thus, our AgNOR score in blood forming elements from RA and RAEB patients was in good accord with recently published findings in relation to the progression from RA to RAEB and RAEB-t. The absence of the expected increase of ribosomal cistron activity in haematopoietic progenitors at the RA stage might be explained by extensive apoptosis.
Our findings showed that the AgNOR score in promyelocytes from patients with RA correlated closely with those of blasts (r = 0.7), Er-I (r = 0.86), myelocytes (r = 0.71), and with the content of bone marrow myelocytes (r = 0.5). In addition, the percentage of bone marrow promyelocytes showed a significant correlation with the numbers of bone marrow myelocytes (r = 0.58) and with cell cycle analysis of bone marrow cells in myelodysplastic syndromes (MDS). Therefore, the numbers of promyelocytes showed a strong correlation with those of blasts, AgNOR counts, and mononuclear cell count in patients with acute leukemias. According to our findings, a possible inhibitory effect on MDS haemopoiesis was present at the level of polychromatic normoblasts and myelocytes from patients with RAEB. This conclusion was based on a strong negative correlation between the AgNOR counts in blasts and polychromatic normoblasts and myelocytes. Compared to blasts, AgNOR counts in RA and RAEB megakaryocytes correlated well with those in polychromatic normoblasts and with the numbers of erythrocytes. In our opinion, this observation suggests that megakaryocytic and erythroid lineages arise from a common precursor and have very similar mechanisms controlling gene expression. In conclusion, the AgNOR data illustrate the usefulness of this method for detailed evaluation of aspects of haemopoiesis in physiological and pathological conditions. Moreover, there is some indirect evidence that megakaryocytes can participate in a microenvironment and/or stroma support and restoration, including haematoapoiesis of patients with RA and RAEB.